MedPage Today on MSN

Third-Generation PCSK9 Inhibitor Approved for High Cholesterol

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...
The American Journal of Managed Care

FDA Approves Once-Monthly PCSK9 Injection for LDL-C Reduction

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
Healio

Novel PCSK9 inhibitor recaticimab linked to durable LDL reduction

Please provide your email address to receive an email when new articles are posted on . Less frequent anti-PCSK9 monoclonal antibody dosing is possible with recaticimab. When dosed every 12 weeks, the ...
Fierce Pharma

Cincinnati's LIB scores FDA approval for 3rd-generation PCSK9 drug Lerochol

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...
Healio

Lerodalcibep reduces LDL in well-treated patients with HeFH vs. placebo

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep further reduced LDL vs. placebo in well-treated patients with HeFH. More than 85% of the ...
Business Wire

LIB Therapeutics Announces Positive Results from the Phase 3 Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia (LIBerate-HeFH) Trial

-- Monthly Lerodalcibep achieved both co-Primary Endpoints, with Statistically Significant (p<0.0001) placebo adjusted reductions in mean LDL-Cholesterol in the intent-to-treat population of 58.6% at ...
Medscape

Are We Lowering LDL Cholesterol Sufficiently?

Nat Clin Pract Cardiovasc Med. 2006;3(6):290-291. A positive causal relationship between the concentration of LDL cholesterol and the future risk of cardiovascular events is one of the best-proven ...
MedPage Today

For Short-Term LDL Reduction, Low-Dose Statin is More Effective Than Dietary Supplements

Use of OTC dietary supplements is increasingly common, sometimes replacing guideline-recommended therapies. Rosuvastatin was associated with larger reductions in LDL-C compared with placebo, fish oil, ...

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE ...
Seeking Alpha

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...
Benzinga.com

Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results (CORRECTED)

The treatment discontinuation rate for the obicetrapib arm was 7.6% versus 14.4% for the placebo. Despite the trial hitting its primary endpoint, the company's stock experienced volatility. Ready to ...
Medscape

Driving LDL-C Below 50 mg/dL Cuts Cardiac Event Risk, but Less Than Expected?

LONDON, UK — Achieving LDL-cholesterol levels less than 50 mg/dL with drug therapy, compared with baseline levels, is associated with lowered rates of major adverse cardiovascular events (MACE), but ...